Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Marvell Technology Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Marvell Technology Inc trades at $238.17 (market cap $220.43B). The key difference: Marvell Technology Inc is far larger — about 225.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Marvell Technology Inc pays a 0.1% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Marvell Technology Inc for 43 Days on average.
| MRVI | MRVL | |
|---|---|---|
Market Cap | $977.37M | $220.43B |
Volume | 2,742,564 | 25,874,039 |
Sector | Health | Technology |
52-Week High | $9.00 | $316.43 |
52-Week Low | $2.83 | $73.73 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $1.08B | $221.79B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Marvell Technology (MRVL) trades at $268.73, up 1.08% today, with a bullish technical signal from moving averages and strong analyst support. The company reported three consecutive quarterly EPS beats and projects robust revenue growth, driven by AI and data center demand. Recent news highlights a $120 billion potential deal with Google and raised fiscal 2028 guidance to $18 billion, fueling investor optimism despite high valuation multiples.
Outlook remains positive with a consensus price target of $327.86, implying 22% upside, but risks include elevated P/E of 88.98 and dependence on hyperscaler contracts. Net losses in 2025 contrast with projected 2026 profitability, requiring execution on custom chip growth to justify valuations amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
